Table 1 Overview of the subject collective and individual measurement parameters
N (%); mean ± STD | |
|---|---|
Number of subjects | 51 |
Gender | |
Male | 31 (61 %) |
Female | 20 (39 %) |
Age (years) | 51 ± 11 |
Weight (kg) | 75 ± 14 |
Height (m) | 1.7 ± 0.1 |
BMI (kg/m2) | 25.5 ± 3.5 |
Hepatopathies | |
Hepatitis C | 13 (25 %) |
Hepatitis B | 5 (10 %) |
Non-alcoholic Steatohepatitis (NASH) | 10 (20 %) |
Non-alcoholic fatty liver disease (NAFLD) | 6 (12 %) |
Autoimmune Hepatitis (AIH) | 5 (10 %) |
Toxic liver damage | 3 (6 %) |
Other and Unknown | 9 (17 %) |
Fibrosis stage (Desmet/Scheuer) | |
Stage F0 | 15 (32 %) |
Stage F1 | 10 (21 %) |
Stage F2 | 13 (28 %) |
Stage F3 and F4 | 9 (19 %) |
Tissue cylinder | |
Length (cm) | 1.8 ± 0.6 |
Portal tracts | 7 ± 3 |
Hepatocytes with lipid inclusions | |
Grade 0: <5 % | 34 (67 %) |
Grade 1: 5–30 % | 10 (20 %) |
Grade 2: >30 % | 7 (13 %) |